Jun 16, 2026Metabolic TherapeuticsGLP-1 vs. SGLT2: Which Cardiorenal Benefit Matters Most?GLP-1 receptor agonists and SGLT2 inhibitors can retain benefits together, but kidney, heart-failure, stroke, and MACE evidence differs.glp-1 receptor agonistssglt2 inhibitorscardiorenal outcomesmaceRead article →
Mar 29, 2026Metabolic DiseaseSGLT2 Inhibitors vs GLP-1 Drugs: Kidney Study ResultsSGLT2 inhibitors beat GLP-1 drugs on some kidney outcomes, but mortality and albuminuria complicate the choice. What the first head-to-head study found today.sglt2 inhibitorsglp-1 receptor agoniststype 2 diabeteskidney protectionRead article →